Information Provided By: 
Fly News Breaks for July 9, 2015
HALO
Jul 9, 2015 | 07:15 EDT
UBS raised Halozyme's price target to $28 to reflect recent data at ASCO conference as well as new ENHANZE partnerships and sees additional upside in shares from Stage 2 of Study '202 in pancreatic cancer and docetaxel adn PD-1 combination studies expected over the next 6-12 months. UBS rates Halozyme shares a Buy.
News For HALO From the Last 2 Days
There are no results for your query HALO
